in the absence of a submission from the holder of the marketing authorisation:
bosutinib (Bosulif®) is not recommended for use within NHSScotland.
Indication under review: Treatment of adult patients with newly diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukaemia.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.
Download detailed advice88KB (PDF)
- Medicine name:
- bosutinib (Bosulif)
- SMC ID:
- For treatment of adult patients with newly diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukaemia.
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Not recommended
- Date advice published:
- 13 August 2018